(Guest Lecture) January 2021 Modifiable risk factors that affect Myeloma Pt. 1

Can only a percentage of your myeloma cells possess 17p deletion? How is that percentage determined?

Can only one allele of chromosome 17 have a deletion? How does this affect risk?

How has myeloma treatment become more personalized based on genetics?

What is CRSPR? How will it be used in myeloma?

What is the MyDrug trial?

What are the challenges of precision medicine in myeloma?

How is myeloma treatment personalized for varying levels of fitness and frailty?

How is myeloma treatment personalized to genetic markers now and what may the future of precision medicine in myeloma be?

What is precision medicine?

Will del 17p and other chromosomal abnormalities go away after an auto ASCT? If not why may it not be detected?